A detailed history of Price T Rowe Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,768,010 shares of VRTX stock, worth $798 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,768,010
Previous 2,211,674 20.06%
Holding current value
$798 Million
Previous $1.04 Billion 20.68%
% of portfolio
0.09%
Previous 0.12%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $204 Million - $224 Million
-443,664 Reduced 20.06%
1,768,010 $822 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $896 Million - $1.11 Billion
-2,281,748 Reduced 50.78%
2,211,674 $1.04 Billion
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $568 Million - $622 Million
-1,393,990 Reduced 23.68%
4,493,422 $1.88 Billion
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $330 Million - $395 Million
-962,654 Reduced 14.05%
5,887,412 $2.4 Billion
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $30.9 Million - $33.1 Million
91,308 Added 1.35%
6,850,066 $2.38 Billion
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $53 Million - $59.3 Million
168,568 Added 2.56%
6,758,758 $2.38 Billion
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $536 Million - $611 Million
1,892,523 Added 40.29%
6,590,190 $2.08 Billion
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $132 Million - $148 Million
-460,287 Reduced 8.92%
4,697,667 $1.36 Billion
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $53.5 Million - $59.7 Million
195,271 Added 3.93%
5,157,954 $1.49 Billion
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $80.4 Million - $100 Million
-342,014 Reduced 6.45%
4,962,683 $1.4 Billion
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $25.8 Million - $30.4 Million
-116,594 Reduced 2.15%
5,304,697 $1.38 Billion
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $49 Million - $61.9 Million
-276,956 Reduced 4.86%
5,421,291 $1.19 Billion
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $1.34 Billion - $1.5 Billion
-7,400,245 Reduced 56.5%
5,698,247 $1.03 Billion
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $647 Million - $763 Million
-3,451,384 Reduced 20.85%
13,098,492 $2.64 Billion
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $637 Million - $743 Million
-3,077,048 Reduced 15.68%
16,549,876 $3.56 Billion
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $4.06 Billion - $5.42 Billion
19,626,924 New
19,626,924 $4.63 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.